Brand Name

Lexapro

Generic Name
Escitalopram
View Brand Information
FDA approval date: August 14, 2002
Classification: Serotonin Reuptake Inhibitor
Form: Tablet, Capsule, Solution

What is Lexapro (Escitalopram)?

Lexapro is indicated for the treatment of: major depressive disorder in adults and pediatric patients 12 years of age and older., generalized anxiety disorder in adults and pediatric patients 7 years of age and older. Lexapro is a selective serotonin reuptake inhibitor indicated for the: treatment of major depressive disorder in adults and pediatric patients 12 years of age and older treatment of generalized anxiety disorder in adults and pediatric patients 7 years and older
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Escitalopram and Language Intervention for Subacute Aphasia (ELISA)

Summary: In this project, the investigators will investigate the effects of a selective serotonin reuptake inhibitor (SSRI), escitalopram, on augmenting language therapy effectiveness, as measured by naming untrained pictures and describing pictures, in individuals with aphasia in the acute and subacute post stroke period (i.e., within three months post stroke).

Efficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder

Summary: The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to ...

Efficacy of a Combination of Chronotherapeutics for the Treatment of Major Depressive Episode (MDE) With Insomnia: a Multicenter, Randomized, 2*2 Factorial, Double-blind, Placebo-controlled Trial

Summary: Major Depressive Disorder (MDD) affects 5% of the global population and is the second leading cause of disability worldwide. Despite the widespread use of antidepressants, 50-60% of patients do not respond adequately after 8 weeks of treatment. Insomnia, present in approximately 85% of individuals with MDD, is a frequent and persistent symptom that contributes to poor treatment outcomes. Targeting...